华北制药
(600812)
| 流通市值：79.27亿 | | | 总市值：79.27亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 4,219,592,946.76 | 2,153,167,876.49 | 9,241,652,953.8 | 7,484,828,636.64 |
| 营业总成本 | 4,139,210,250.29 | 2,088,645,071.89 | 8,957,348,085.02 | 7,258,017,573.93 |
| 其他经营收益 | | | | |
| 营业利润 | 124,390,877.94 | 66,574,787.5 | 353,971,603.38 | 286,904,212.36 |
| 利润总额 | 123,930,471.17 | 66,281,203.77 | 357,408,948.04 | 287,215,555.62 |
| 净利润 | 90,872,547.55 | 49,376,883.19 | 257,453,101.84 | 211,538,869.17 |
| 每股收益 | | | | |
| 其他综合收益 | -2,909,537.26 | -1,662,299.38 | -14,247,723.02 | -209,831.87 |
| 综合收益总额 | 87,963,010.29 | 47,714,583.81 | 243,205,378.82 | 211,329,037.3 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 7,978,230,388.02 | 8,265,350,407.22 | 8,131,296,097.38 | 8,336,620,392.11 |
| 非流动资产: | | | | |
| 非流动资产合计 | 13,150,393,426.59 | 13,186,660,450.88 | 13,260,607,289.58 | 13,200,664,532.45 |
| 资产总计 | 21,128,623,814.61 | 21,452,010,858.1 | 21,391,903,386.96 | 21,537,284,924.56 |
| 流动负债: | | | | |
| 流动负债合计 | 10,499,830,645.19 | 11,436,666,528.96 | 12,399,264,384.69 | 12,409,673,422.38 |
| 非流动负债: | | | | |
| 非流动负债合计 | 3,760,831,089.09 | 3,081,452,596 | 2,107,642,023.68 | 2,453,582,912.28 |
| 负债合计 | 14,260,661,734.28 | 14,518,119,124.96 | 14,506,906,408.37 | 14,863,256,334.66 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,518,386,538.1 | 5,549,821,971.61 | 5,514,831,272.76 | 5,505,224,974.65 |
| 股东权益合计 | 6,867,962,080.33 | 6,933,891,733.14 | 6,884,996,978.59 | 6,674,028,589.9 |
| 负债和股东权益合计 | 21,128,623,814.61 | 21,452,010,858.1 | 21,391,903,386.96 | 21,537,284,924.56 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 3,314,806,363.59 | 1,501,402,325.39 | 7,839,785,548.21 | 5,641,276,009.82 |
| 经营活动现金流出小计 | 2,763,993,222.78 | 1,342,736,168.98 | 6,663,246,292.21 | 4,979,830,131.48 |
| 经营活动产生的现金流量净额 | 550,813,140.81 | 158,666,156.41 | 1,176,539,256 | 661,445,878.34 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 95,012,000 | 40,200 | 61,083,992.36 | 60,596,232.8 |
| 投资活动现金流出小计 | 256,271,661.75 | 122,790,203.99 | 842,012,200.76 | 680,002,187.69 |
| 投资活动产生的现金流量净额 | -161,259,661.75 | -122,750,003.99 | -780,928,208.4 | -619,405,954.89 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 7,908,358,000 | 3,983,598,000 | 10,812,750,000 | 7,060,360,000 |
| 筹资活动现金流出小计 | 8,746,729,746.8 | 4,320,586,932.76 | 11,198,014,329.97 | 7,193,011,402.2 |
| 筹资活动产生的现金流量净额 | -838,371,746.8 | -336,988,932.76 | -385,264,329.97 | -132,651,402.2 |
| 汇率变动对现金及现金等价物的影响 | -11,699,627.56 | -5,914,930.01 | 477,331.53 | 3,040,427.58 |
| 现金及现金等价物净增加额 | -460,517,895.3 | -306,987,710.35 | 10,824,049.16 | -87,571,051.17 |
| 期末现金及现金等价物余额 | 812,710,106.88 | 966,240,291.83 | 1,273,228,002.18 | 1,174,832,901.85 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -460,517,895.3 | - | 10,824,049.16 | - |